Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/202075
Title: | Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials |
Author: | Huerta, Miguel Á. García, Miguel M. García Parra, Beliu Serrano Afonso, Ancor Paniagua, Nancy |
Keywords: | Herpes zòster Neuropaties perifèriques Farmacologia Shingles (Disease) Peripheral neuropathies Pharmacology |
Issue Date: | 20-Aug-2023 |
Publisher: | MDPI AG |
Abstract: | The pharmacological treatment of postherpetic neuralgia (PHN) is unsatisfactory, and there is a clinical need for new approaches. Several drugs under advanced clinical development are addressed in this review. A systematic literature search was conducted in three electronic databases (Medline, Web of Science, Scopus) and in the ClinicalTrials.gov register from 1 January 2016 to 1 June 2023 to identify Phase II, III and IV clinical trials evaluating drugs for the treatment of PHN. A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) a2d subunit inhibition (crisugabalin, mirogabalin and prega-balin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). In brief, there are several drugs in ad-vanced clinical development for treating PHN with some of them reporting promising results. AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/ijms241612987 |
It is part of: | International Journal of Molecular Sciences, 2023, vol. 24, num. 16 |
URI: | http://hdl.handle.net/2445/202075 |
Related resource: | https://doi.org/10.3390/ijms241612987 |
ISSN: | 1422-0067 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ijms-24-12987.pdf | 1.39 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License